2017
Prognostic value of NK and T-lymphocytes markers in operable non-small cell lung cancer (NSCLC).
Skrzypski M, Szymanowska-Narloch A, Jassem E, Marczyk M, Polanska J, Biernat W, Rzyman W, Maciejewska A, Pawlowski R, Jassem J. Prognostic value of NK and T-lymphocytes markers in operable non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2017, 35: 11556-11556. DOI: 10.1200/jco.2017.35.15_suppl.11556.Peer-Reviewed Original ResearchNon-small cell lung cancerRelapsed non-small cell lung cancerDistant metastasis-free survivalNormal lung parenchymaPrognostic valueLung parenchymaOperable non-small cell lung cancerEarly-stage non-small cell lung cancerShorter distant metastasis-free survivalStage non-small cell lung cancerNK activation markersNSCLC histological typesExpression of CXCR3Immune-targeted therapiesEndothelin receptor type BIIIA NSCLC patientsMetastasis-free survivalNK cell markersCell lung cancerT lymphocyte markersNormal lung tissuesPrimary resectionFree survivalNK cellsNSCLC patientsStage I non-small-cell lung cancer: long-term results of lobectomy versus sublobar resection from the Polish National Lung Cancer Registry†
Dziedzic R, Żurek W, Marjański T, Rudziński P, Orłowski TM, Sawicka W, Marczyk M, Polańska J, Rzyman W. Stage I non-small-cell lung cancer: long-term results of lobectomy versus sublobar resection from the Polish National Lung Cancer Registry†. European Journal Of Cardio-Thoracic Surgery 2017, 52: 363-369. PMID: 28402455, DOI: 10.1093/ejcts/ezx092.Peer-Reviewed Original ResearchConceptsStage I NSCLCLung Cancer RegistryWedge resectionCell lung cancerOverall survivalSurvival rateCancer RegistryLung cancerCox proportional hazard ratiosPropensity score-matched analysisProportional hazard ratiosGroup of patientsTreatment of patientsLong-term resultsMethod of resectionLobar resectionHazard ratioSublobar resectionMediastinal lymphadenectomySurgical treatmentPatient groupRetrospective analysisSegmentectomyLobectomyStudy group
2011
Comparison of peptide cancer signatures identified by mass spectrometry in serum of patients with head and neck, lung and colorectal cancers: association with tumor progression.
Pietrowska M, Polańska J, Suwiński R, Wideł M, Rutkowski T, Marczyk M, Domińczyk I, Ponge L, Marczak L, Polański A, Widłak P. Comparison of peptide cancer signatures identified by mass spectrometry in serum of patients with head and neck, lung and colorectal cancers: association with tumor progression. International Journal Of Oncology 2011, 40: 148-56. PMID: 21894432, DOI: 10.3892/ijo.2011.1186.Peer-Reviewed Original ResearchConceptsLung cancer samplesCancer samplesHealthy donorsSerum proteomeNon-small cell lung cancerNeck squamous cell cancerSquamous cell cancerCell lung cancerAdvanced cancer casesSera of patientsColorectal cancer samplesCancer signaturesInter-group analysisPeptide signaturesCell cancerClinical stageColorectal cancerCancer patientsLung cancerNeck cancerColorectal adenocarcinomaCancer casesSerum amyloidHealthy volunteersBlood samples